September 2016

home / publications / contemporary-radiation-oncology / september-2016

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

Vivek N. Patel, MD;Felix M. Chinea, MD;Deukwoo Kwon, PhD;Gustavo Fernandez, MD;Hanmath J Neboori, MD;Michael A. Samuels, MD;Laura M. Freedman, MD;Nagy M. Elsayad;Donald Weed, MD;Elizabeth Franzmann, MD;Chukwuemeka V. Ikpeazu, MD, PhD;Matthew C. Abramowitz, MD

March 19th 2017

Article

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis

Rupen Garg, BS;Qinyu Chen, MHS;Yin Zhang, PhD;Ariel E. Marciscano, MD;Jing Zeng, MD;Robert J. Arceci, MD, PhD;Stephanie A. Terezakis, MD

March 12th 2017

Article

Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.

Factors Influencing Patient-Reported Rectal Toxicity Following External Beam Radiation Therapy for Prostate Cancer

Gerard E. Heath BS, Daniel A. Hamstra MD, Dean A. Shumway MD

March 10th 2017

Article

Developing and validating a predictive model for patient-reported health-related quality of life remains an elusive target, and one that has great potential to further improve satisfaction with outcome following prostate cancer treatment in a great number of prostate cancer survivors.